期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 568, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2019.118530
关键词
Co-encapsulants; Gene silencing; Metastatic colorectal cancer; PLGA nanoparticles; RNA interference technology
资金
- Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000012]
- FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020
- Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior [POCI-01-0145-FEDER-007274]
- CESPU/IINFACTS
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the world, mainly due to distant metastases events. The metastatic CRC (mCRC) stages are resistant to the therapeutic recommended. Therefore, it urges the development of more efficient strategies to impair the disease. Small interfering RNA (siRNA) is a well-known silencing tool with impact on targeted cancer therapy, even though in vivo challenges difficult its clinical application. Here, multiple solutions to overcome the extracellular and intracellular barriers encountered by intravenous delivery of siRNA are discussed. Moreover, it is emphasized the association of siRNA with nanoparticles to enable the long-term release and to counteract the toxicity issues of siRNA. Particular attention is paid on the potential of poly(lactic-co-glycolic acid) (PLGA) nanoparticles for systemic siRNA delivery in mCRC. Despite of being less used so far due to technological difficulties, multiple strategies to successfully encapsulate siRNA into PLGA nanocarriers are summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据